000099217 001__ 99217 000099217 005__ 20220120225836.0 000099217 0247_ $$2doi$$a10.3390/jcm9123850 000099217 0248_ $$2sideral$$a122640 000099217 037__ $$aART-2020-122640 000099217 041__ $$aeng 000099217 100__ $$aChaure-Pardos, Armando 000099217 245__ $$aFactors Associated with the Prescribing of High-Intensity Statins 000099217 260__ $$c2020 000099217 5060_ $$aAccess copy available to the general public$$fUnrestricted 000099217 5203_ $$aIn this study, we investigated the relationship between sociodemographic, clinical, anthropometric, and lifestyle characteristics and the type of statin prescribed for primary prevention of cardiovascular disease (CVD). We conducted an observational study in workers who began statin treatment. Statin therapy was categorized as "high-intensity" or "low-moderate-intensity". Workers were classified according to the alignment of their statin therapy with the recommended management practices. Logistic regression models were used to evaluate the association between the different variables studied and the probability of being prescribed high-intensity statins. The only variables associated with a higher probability of being treated with high-intensity statins were increased physical activity (>40 versus <20 METs (metabolic equivalent of task) h/wk; odds ratio (OR), 1.65; 95%CI, 1.08-2.50) and, in diabetics, higher low-density lipoprotein cholesterol (LDL-C) levels (>= 155 mg/dL versus <155 mg/dL; OR, 4.96; 95%CI, 1.29-19.10). The model that best predicted treatment intensity included LDL-C, diabetes, hypertension, smoking, and age (area under the Receiver Operating Characteristic curve (AUC), 0.620; 95%CI, 0.574-0.666). The prescribing and type of statin used in primary CVD prevention did not correspond with the indications in current guidelines. The probability of receiving high-intensity statins was higher in diabetics with high LDL-C levels and in more physically active individuals. These findings underscore the great variability and uncertainty in the prescribing of statins. 000099217 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER-FIS/PI17-01704 000099217 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000099217 590__ $$a4.241$$b2020 000099217 591__ $$aMEDICINE, GENERAL & INTERNAL$$b39 / 169 = 0.231$$c2020$$dQ1$$eT1 000099217 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000099217 700__ $$0(orcid)0000-0002-6671-5661$$aMalo, Sara$$uUniversidad de Zaragoza 000099217 700__ $$0(orcid)0000-0002-7194-8275$$aRabanaque, María José$$uUniversidad de Zaragoza 000099217 700__ $$0(orcid)0000-0003-1858-4481$$aArribas, Federico$$uUniversidad de Zaragoza 000099217 700__ $$0(orcid)0000-0003-0604-5042$$aMoreno-Franco, María Belén$$uUniversidad de Zaragoza 000099217 700__ $$0(orcid)0000-0001-7293-701X$$aAguilar-Palacio, Isabel$$uUniversidad de Zaragoza 000099217 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ. 000099217 773__ $$g9, 12 (2020), 3850 [12 pp]$$pJ. clin.med.$$tJournal of Clinical Medicine$$x2077-0383 000099217 8564_ $$s411104$$uhttps://zaguan.unizar.es/record/99217/files/texto_completo.pdf$$yVersión publicada 000099217 8564_ $$s2452896$$uhttps://zaguan.unizar.es/record/99217/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000099217 909CO $$ooai:zaguan.unizar.es:99217$$particulos$$pdriver 000099217 951__ $$a2022-01-20-22:57:41 000099217 980__ $$aARTICLE